Arcutis Biotherapeutics, Inc.(ARQT)Stock Analysis

ARQT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Arcutis Biotherapeutics, Inc. (ARQT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ARQT at 41.2/100 on a 32-signal composite quality model, placing it at rank #1,908 of 2,879 stocks — the bottom half of the AI-ranked universe. ARQT scores in the top quartile across revenue growth (98.2), institutional flow (79.5). Areas of concern include balance sheet strength (17.1) and free cash flow (20.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Arcutis Biotherapeutics, Inc. reports quarterly revenue of $105.4M, net income of $-11.3M, free cash flow of $2.2M. Top institutional holders of ARQT by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, Frazier Life Sciences Management, L.P., BlackRock,, based on the most recent SEC filings. ARQT trades on the Nasdaq exchange and files with the SEC under CIK 1787306. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ARQT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcutis Biotherapeutics, Inc. directly from SEC EDGAR.